🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsBeen on the reta waiting list for months - anyone heard anything? — July 2024

Been on the reta waiting list for months - anyone heard anything? — July 2024

andrew_nyc Sun, Nov 24, 2024 at 1:48 AM 12 replies 1,895 viewsPage 1 of 3
This thread is more than 18 months old. Information may be outdated. Consider searching for more recent discussions.
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Nov 24, 2024 at 1:48 AM#1

Sceptical rather than excited about the triple agonist, and I would like somebody to talk me out of the scepticism with data rather than enthusiasm.

The narrow version of the question is why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose.

Numbers rather than impressions, if you have them.

49 19Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 46 others
Reply Quote Save Share Report
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Nov 24, 2024 at 1:53 AM#2

Taking the question as asked, rather than the general version of it. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

48 18ricardo_MIA, BrianDallas92, labquiet_amy and 45 others
Reply Quote Save Share Report
sarah_TO
Member
278
1,234
Sep 2024
Toronto, CA
Nov 24, 2024 at 1:58 AM#3
CarlaRPh_TPA said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Agreeing with CarlaRPh_TPA, and the qualification matters more than the agreement. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.

Last edited: Nov 24, 2024 at 5:58 AM
47 17GraceAZ_72, carl_compliance, DanielChem_CHI and 44 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
mia_MS2
New Member
8
23
Jun 2026
Ann Arbor, MI
Nov 24, 2024 at 2:03 AM#4
andrew_nyc said:
Sceptical rather than excited about the triple agonist, and I would like somebody to talk me out of the scepticism with data rather than enthusiasm.

Mine went the same way, slower. Posting only so the count is not one.

46 16steve_okc, dave_SLC, FDA_TrackerJim and 43 others
Reply Quote Save Share Report
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Nov 24, 2024 at 2:30 AM#5

From the other side of the consultation, briefly. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

Last edited: Nov 24, 2024 at 5:30 AM
45 15SandraNC_45, Dr.EndoIndy, tom_AK and 42 others
Reply Quote Save Share Report

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register